WO2017075389A8 - Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells - Google Patents

Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells Download PDF

Info

Publication number
WO2017075389A8
WO2017075389A8 PCT/US2016/059375 US2016059375W WO2017075389A8 WO 2017075389 A8 WO2017075389 A8 WO 2017075389A8 US 2016059375 W US2016059375 W US 2016059375W WO 2017075389 A8 WO2017075389 A8 WO 2017075389A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
generating
immunotherapeutic
stem
Prior art date
Application number
PCT/US2016/059375
Other languages
French (fr)
Other versions
WO2017075389A1 (en
Inventor
Gay M. CROOKS
Amelie Montel-Hagen
Christopher S. SEET
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562248931P priority Critical
Priority to US62/248,931 priority
Priority to US201562265204P priority
Priority to US62/265,204 priority
Priority to US201662359456P priority
Priority to US62/359,456 priority
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority claimed from EA201891059A external-priority patent/EA201891059A1/en
Publication of WO2017075389A1 publication Critical patent/WO2017075389A1/en
Publication of WO2017075389A8 publication Critical patent/WO2017075389A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0037Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062General methods for three-dimensional culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669Bone marrow stromal cells; Whole bone marrow
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/22Zinc; Zn chelators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • C12N2500/25Insulin-transferrin; Insulin-transferrin-selenium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/38Vitamins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/99Serum-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/125Stem cell factor [SCF], c-kit ligand [KL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/145Thrombopoietin [TPO]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2304Interleukin-4 (IL-4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2306Interleukin-6 (IL-6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2307Interleukin-7 (IL-7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2315Interleukin-15 (IL-15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2321Interleukin-21 (IL-21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/25Tumour necrosing factors [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/003D culture

Abstract

Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.
PCT/US2016/059375 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells WO2017075389A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US201562248931P true 2015-10-30 2015-10-30
US62/248,931 2015-10-30
US201562265204P true 2015-12-09 2015-12-09
US62/265,204 2015-12-09
US201662359456P true 2016-07-07 2016-07-07
US62/359,456 2016-07-07

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP16860902.2A EP3368660A4 (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
AU2016343682A AU2016343682A1 (en) 2015-10-30 2016-10-28 Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
MX2018005274A MX2018005274A (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells.
CA3003145A CA3003145A1 (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
BR112018008648A BR112018008648A2 (en) 2015-10-30 2016-10-28 T cell generation methods from stem cells and immunotherapeutic methods when using T cells
CN201680077607.7A CN108463548A (en) 2015-10-30 2016-10-28 The method of T cell is generated by stem cell and using the immunotherapy method of the T cell
KR1020187015441A KR20180092951A (en) 2015-10-30 2016-10-28 A method for producing T-cells from stem cells and an immunotherapy method using the T-cells
JP2018522655A JP6983771B2 (en) 2015-10-30 2016-10-28 A method for producing T cells from stem cells and an immunotherapeutic method using the T cells.
US15/772,224 US11154573B2 (en) 2015-10-30 2016-10-28 Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
EA201891059A EA201891059A1 (en) 2016-07-07 2016-10-28 METHODS FOR OBTAINING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC METHODS OF T-CELL APPLICATION
SG11201803419PA SG11201803419PA (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
IL258899A IL258899A (en) 2015-10-30 2018-04-24 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
US17/478,875 US20220096553A1 (en) 2015-10-30 2021-09-17 Methods or generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/772,224 A-371-Of-International US11154573B2 (en) 2015-10-30 2016-10-28 Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
US17/478,875 Continuation US20220096553A1 (en) 2015-10-30 2021-09-17 Methods or generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Publications (2)

Publication Number Publication Date
WO2017075389A1 WO2017075389A1 (en) 2017-05-04
WO2017075389A8 true WO2017075389A8 (en) 2018-05-24

Family

ID=58631163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/059375 WO2017075389A1 (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Country Status (13)

Country Link
US (2) US11154573B2 (en)
EP (1) EP3368660A4 (en)
JP (2) JP6983771B2 (en)
KR (1) KR20180092951A (en)
CN (1) CN108463548A (en)
AU (1) AU2016343682A1 (en)
BR (1) BR112018008648A2 (en)
CA (1) CA3003145A1 (en)
IL (1) IL258899A (en)
MX (1) MX2018005274A (en)
SG (1) SG11201803419PA (en)
TW (1) TW201730334A (en)
WO (1) WO2017075389A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872575A (en) * 2019-10-21 2020-03-10 中冠赛尔生物科技(北京)有限公司 In-vitro amplification method of iNKT cells

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US20200080057A1 (en) * 2016-12-13 2020-03-12 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
CN110662831A (en) * 2017-05-26 2020-01-07 凯德药业股份有限公司 Methods of making and using embryonic mesenchymal progenitor cells
CA3067226A1 (en) * 2017-06-16 2018-12-20 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
EP3743510A1 (en) 2018-01-28 2020-12-02 Universite De Geneve Arginase suppression for cancer treatment
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
EP3781177A4 (en) * 2018-04-19 2022-03-02 Baylor College of Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
CN110499291A (en) * 2018-05-16 2019-11-26 西比曼生物科技(香港)有限公司 The method of free serum culture preparation Chimeric antigen receptor T cell
EP3806869A4 (en) * 2018-06-12 2022-04-20 The Regents of the University of California Stem cell-engineered inkt cell-based off -the-shelf cellular therapy
KR20210030373A (en) * 2018-07-13 2021-03-17 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Method for producing γδ T cells
WO2020123015A1 (en) * 2018-10-01 2020-06-18 The Trustees Of Columbia University In The City Of New York Three-dimensional co-culture system for high-throughput testing of therapeutics and diagnostics
WO2020092839A1 (en) * 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109762843A (en) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 A method of general CAR-T cell is prepared using the CD3 positive T cell of derived from cord blood
CN109652376B (en) * 2019-01-08 2021-10-15 创芯国际生物科技(广州)有限公司 Culture medium for 3D culture of ovarian cancer tissues
CN113710257A (en) * 2019-02-24 2021-11-26 盖米达细胞有限公司 Methods of γ δ T cell homing and retention, optionally using natural killer cells, for generating cell compositions for therapy
CN110106144B (en) * 2019-05-17 2021-10-08 苏州大学 Method and kit for inducing hematopoietic stem cells to differentiate into pre-T-lineage cells
EP3998082A1 (en) * 2019-07-10 2022-05-18 National Cancer Center Specific marker for identifying t cells specifically attacking cancer cells
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
CN110499288A (en) * 2019-09-17 2019-11-26 青岛华赛伯曼医学细胞生物有限公司 The kit and its application that external evoked candidate stem cell breaks up to thymus T cells
KR102081418B1 (en) * 2019-09-24 2020-05-26 주식회사 이뮤니스바이오 A medium composition of regulatory t cells derived from peripheral blood mononuclear cells and cultivation method using the same
JPWO2021085576A1 (en) 2019-11-01 2021-05-06
CA3160487A1 (en) * 2019-11-05 2021-05-14 City Of Hope Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof
WO2021110908A1 (en) 2019-12-04 2021-06-10 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Device and process for tissue-engineering and regenerative medicine
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
WO2021252898A1 (en) * 2020-06-12 2021-12-16 Pact Pharma, Inc. Compositions and methods of manufacturing autologous t cell therapies
CN111849913B (en) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
UY39373A (en) * 2020-08-10 2022-02-25 Janssen Biotech Inc MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS-SPECIFIC LYMPHOCYTES
WO2022083667A1 (en) * 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Polypeptides comprising a vaccine specific tcr and a chimeric antigen receptor and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0986635A4 (en) 1997-01-10 2001-11-07 Life Technologies Inc Embryonic stem cell serum replacement
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
JP2003530826A (en) * 1999-11-17 2003-10-21 ユニバーシティー オブ ロチェスター Human ex vivo immune system
US20010026937A1 (en) * 2000-01-11 2001-10-04 Juha Punnonen Monocyte-derived dendritic cell subsets
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
JP2006519020A (en) 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Selective regulation of TLR-mediated biological activity
US7795404B1 (en) 2003-08-08 2010-09-14 Five Prime Therapeutics, Inc. Human soluble notch receptor ligands
WO2005070120A2 (en) * 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
WO2007027226A2 (en) 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
ES2829549T3 (en) 2005-10-18 2021-06-01 Prec Biosciences Rationally Engineered Meganucleases with Altered DNA Binding Affinity and Sequence Specificity
EP1815863A1 (en) 2006-02-03 2007-08-08 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of TLR3 agonists for the treatment of neurodegenerative disorders
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US10059923B2 (en) * 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
US10350243B2 (en) * 2008-01-30 2019-07-16 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
WO2009136874A1 (en) * 2008-05-09 2009-11-12 Agency For Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
CA2736851A1 (en) 2008-09-11 2010-03-18 Lung-Ji Chang System and method for producing t cells
EP2352756B1 (en) 2008-11-24 2012-09-19 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH High affinity t cell receptor and use thereof
CN102388130B (en) 2009-02-27 2014-08-27 细胞动力国际有限公司 Differentiation of pluripotent cells
WO2011101468A1 (en) 2010-02-22 2011-08-25 Université Pierre Et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
WO2012027017A2 (en) 2010-06-25 2012-03-01 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
WO2014039044A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
ES2824024T3 (en) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
WO2014138315A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Heparanase expression in human t lymphocytes
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872575A (en) * 2019-10-21 2020-03-10 中冠赛尔生物科技(北京)有限公司 In-vitro amplification method of iNKT cells

Also Published As

Publication number Publication date
SG11201803419PA (en) 2018-05-30
IL258899A (en) 2018-06-28
MX2018005274A (en) 2019-09-19
AU2016343682A1 (en) 2018-06-14
EP3368660A4 (en) 2019-04-24
KR20180092951A (en) 2018-08-20
WO2017075389A1 (en) 2017-05-04
BR112018008648A2 (en) 2018-11-27
CN108463548A (en) 2018-08-28
CA3003145A1 (en) 2017-05-04
JP2022033812A (en) 2022-03-02
US11154573B2 (en) 2021-10-26
US20220096553A1 (en) 2022-03-31
TW201730334A (en) 2017-09-01
JP2018533364A (en) 2018-11-15
EP3368660A1 (en) 2018-09-05
US20190231817A1 (en) 2019-08-01
JP6983771B2 (en) 2021-12-17

Similar Documents

Publication Publication Date Title
WO2017075389A8 (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
UA124375C2 (en) Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
WO2016090178A3 (en) Processes for producing exosomes in reduced oxygen culture conditions
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
WO2012109208A3 (en) Hematopoietic precursor cell production by programming
WO2012006440A3 (en) Endothelial cell production by programming
MX2018001324A (en) Crystalline form of lorlatinib free base.
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX2018004600A (en) Natural killer cells and ilc3 cells and uses thereof.
WO2017115128A3 (en) Vector-free delivery of gene editing proteins and compositions to cells and tissues
MX2019011040A (en) Compositions and methods for enhanced gene expression.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
WO2017051347A3 (en) Cells and method of cell culture
EP3612623A4 (en) Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
MY178060A (en) Methods of preparing a poloxamer for use in cell culture medium
MX2015011781A (en) Cell culture media and methods of antibody production.
AU2015208482A1 (en) Fusion protein inhibiting angiogenesis or growth and use thereof
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
WO2016081032A3 (en) Mesenchymal stem cells derived from induced pluripotent stem cells
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
WO2019002512A3 (en) Engineered and fully-functional customized glycoproteins
WO2015051342A3 (en) Compositions and methods for modulating biomass productivity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16860902

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3003145

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11201803419P

Country of ref document: SG

Ref document number: 258899

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/005274

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018522655

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018008648

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 201891059

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20187015441

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016860902

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016343682

Country of ref document: AU

Date of ref document: 20161028

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018008648

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180427